Calendar

An AMCP Market Insights Webinar.

This webinar distills critical highlights to empower US managed care pharmacists. We’ll dive deep into real-world barriers beyond the clinic, exploring how SDOH, coverage gaps, care fragmentation, and side effect management influence treatment success. Gain evidence-based strategies and payer-centric tools to bridge these gaps, foster equitable access, and deliver measurable value in a competitive market.

Attendees will emerge equipped with forward-thinking insights to transform AD care delivery, from rethinking prior authorizations to leveraging real-world data for smarter decision-making.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Otsuka Pharmaceutical Development & Commercialization, Inc.

ADHD is a complex neurodevelopmental disorder encompassing broad symptoms. Current pharmacologic treatments primarily address core symptoms with limited data on their impact on associated features. Evidence underscores the potential importance of three monoamines in ADHD presentation: DA, NE, and 5-HT.

This session covers efficacy and safety of a potential first-in-class NDSRI for ADHD treatment in children, adolescents, and adults. This agent is investigational and not FDA-approved.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Takeda Oncology.

AMCP and Takeda Oncology are pleased to invite you to a PIE webinar on rusfertide, an investigational, first‑in‑class hepcidin mimetic being studied for the treatment of polycythemia vera (PV)—a chronic blood disorder characterized by the overproduction of red blood cells. We’ll review the unmet need, key clinical data, and anticipated product profile, followed by a brief Q&A. We look forward to your participation.

This webinar is offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Takeda Pharmaceuticals.

Narcolepsy Type 1 (NT1) is a rare, chronic neurologic disorder caused by loss of orexin (hypocretin) neurons and marked by excessive daytime sleepiness and cataplexy. Beyond the classic pentad, additional manifestations can affect many aspects of daily functioning. Existing treatments focus on symptom relief alone, as many treated patients report residual symptoms and ongoing impairment. These limitations underscore the need to investigate therapies that directly target orexin deficiency in NT1.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.